Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism

Omri Cohen, Walter Ageno

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Anticoagulants have been in use for nearly a century for the treatment and prevention of venous and arterial thromboembolic disorders. The most dreaded complication of anticoagulant treatment is the occurrence of bleeding, which may be serious and even life-threatening. All available anticoagulants, which target either multiple coagulation factors or individual components of the tissue factor (TF) factor VIIa or the common pathways, have the potential to affect hemostasis and thus to increase bleeding risk in treated patients. While direct oral anticoagulants introduced an improvement in care for eligible patients in terms of safety, efficacy, and convenience of treatment, there remain unmet clinical needs for patients requiring anticoagulant drugs. Anticoagulant therapy is sometimes avoided for fear of hemorrhagic complications, and other patients are undertreated due to comorbidities and the perception of increased bleeding risk. Evidence suggests that the contact pathway of coagulation has a limited role in initiating physiologic in vivo coagulation and that it contributes to thrombosis more than it does to hemostasis. Because inhibition of the contact pathway is less likely to promote bleeding, it is an attractive target for the development of anticoagulants with improved safety. Preclinical and early clinical data indicate that novel agents that selectively target factor XI or factor XII can reduce venous and arterial thrombosis without an increase in bleeding complications.

Original languageEnglish
Pages (from-to)495-505
Number of pages11
JournalHematology. American Society of Hematology. Education Program
Issue number1
StatePublished - 9 Dec 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 by The American Society of Hematology.


Dive into the research topics of 'Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism'. Together they form a unique fingerprint.

Cite this